Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030840 | 0.88 | TGFBR1 (0.53) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL14750976 | 0.87 | TGFBR1 (0.52) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL27077008 | 0.85 | TGFBR1 (0.50) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL4250153 | 0.84 | TGFBR1 (0.63) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL14739393 | 0.84 | TGFBR1 (0.49) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL14108205 | 0.83 | KDM4E (0.69) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL14739275 | 0.82 | TGFBR1 (0.48) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL23728644 | 0.81 | TGFBR1 (0.54) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL1649636 | 0.81 | TGFBR1 (0.54) | TGFBR1GAAKDM4EGLAPIK3CD | |
| SCHEMBL12928396 | 0.81 | KDM4E (0.55) | TGFBR1GAAKDM4EGLAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-9199981-B2 | Compounds and compositions as C-kit kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-9199981-B2 | Compounds and compositions as C-kit kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-9199981-B2 | Compounds and compositions as C-kit kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| WO-2013033203-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033116-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033116-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | TGFBR1 2326/4885GAA 726/4885KDM4E 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.